By integrating network pharmacology, molecular docking, and molecular dynamics simulation analyses, we identified VEGFA and VEGFR2 as key targets of farrerol in the treatment of CRC, which were subsequently validated through in vitro experiments. This evidence concerns the gene KDR and colorectal carcinoma.